On Thursday, Ingevity hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 81, up from 74 the day before.
Hone Your Stock-Picking Skills By Focusing On These Factors
This exclusive rating from Investor's Business Daily identifies price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the best stocks often have an RS Rating north of 80 as they begin their biggest runs.
Ingevity is trying to complete a double bottom with a 50.09 buy point. See if it can break out in volume at least 40% higher than normal.
Ingevity saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 111%. Revenue rose from -20% to -16%. Look for the next report on or around Jul. 30.
The company holds the No. 5 rank among its peers in the Chemicals-Specialty industry group. Niagen Bioscience is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
